OPK (OPKO Health Inc.) stock is in for a key growth catalyst

In the latest session, OPKO Health Inc. (NASDAQ: OPK) closed at $1.33 down -5.00% from its previous closing price of $1.40. In other words, the price has decreased by -$0.0700 from its previous closing price. On the day, 2591595 shares were traded. OPK stock price reached its highest trading level at $1.4000 during the session, while it also had its lowest trading level at $1.2850.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Ratios:

For a deeper understanding of OPKO Health Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.30 and its Current Ratio is at 1.50. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.10.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 15, 2022, initiated with a Buy rating and assigned the stock a target price of $3.

On June 21, 2021, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $7.Ladenburg Thalmann initiated its Buy rating on June 21, 2021, with a $7 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 22 when FROST PHILLIP MD ET AL bought 300,000 shares for $1.49 per share. The transaction valued at 446,673 led to the insider holds 198,831,694 shares of the business.

FROST PHILLIP MD ET AL bought 200,000 shares of OPK for $319,424 on Nov 09. The CEO & Chairman now owns 198,531,694 shares after completing the transaction at $1.60 per share. On Oct 27, another insider, FROST PHILLIP MD ET AL, who serves as the CEO & Chairman of the company, bought 100,000 shares for $1.82 each. As a result, the insider paid 182,006 and bolstered with 198,331,694 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.83 while its Price-to-Book (P/B) ratio in mrq is 0.61.

Stock Price History:

Over the past 52 weeks, OPK has reached a high of $3.78, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is 1.3886, while the 200-Day Moving Average is calculated to be 2.2002.

Shares Statistics:

For the past three months, OPK has traded an average of 2.49M shares per day and 2.67M over the past ten days. A total of 750.40M shares are outstanding, with a floating share count of 416.76M. Insiders hold about 0.40% of the company’s shares, while institutions hold 24.70% stake in the company. Shares short for OPK as of Oct 13, 2022 were 37.44M with a Short Ratio of 38.40M, compared to 38.15M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.85% and a Short% of Float of 8.91%.

Earnings Estimates

There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.13, while EPS last year was $0.04. The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.06 and low estimates of -$0.12.

Analysts are recommending an EPS of between -$0.38 and -$0.49 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.18, with 5 analysts recommending between $0.14 and -$0.39.

Revenue Estimates

A total of 5 analysts believe the company’s revenue will be $183.51M this quarter.It ranges from a high estimate of $215.8M to a low estimate of $166.5M. As of the current estimate, OPKO Health Inc.’s year-ago sales were $385.81M, an estimated decrease of -52.40% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $181.35M, a decrease of -54.80% less than the figure of -$52.40% in the same quarter last year. There is a high estimate of $185.5M for the next quarter, whereas the lowest estimate is $178.8M.

A total of 4 analysts have provided revenue estimates for OPK’s current fiscal year. The highest revenue estimate was $1.01B, while the lowest revenue estimate was $987.33M, resulting in an average revenue estimate of $995.61M. In the same quarter a year ago, actual revenue was $1.77B, down -43.90% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $924.26M in the next fiscal year. The high estimate is $1.14B and the low estimate is $752.6M. The average revenue growth estimate for next year is down -7.20% from the average revenue estimate for this year.